To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Illumina Expands Services Agreement with GSK
Illumina, Inc. has announced that it has expanded the scope of its multi-year, genotyping services agreement with GlaxoSmithKline.
Under the terms of the agreement, Illumina will begin to use Sentrix® HumanHap550 BeadChips for a series of whole-genome association studies for GSK.
The study involves genotyping a collection of 2,000 case and control DNA samples provided by GSK for a specific disease, detail for which was not provided.
According to Jay Flatley, Illumina President and CEO, "We're very pleased to deepen our longstanding relationship with GlaxoSmithKline."
"This agreement underscores the increasing rate at which pharmaceutical and biotech firms are adopting genotyping technology for discovery and pharmacogenomic applications."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
